Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography

The transitional association between β-amyloid pathology and regional brain atrophy

(2015) Philip S. Insel et al.   Alzheimers & Dementia

Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation

(2015) Sylvia Villeneuve et al.   BRAIN

Measurement of Longitudinal  -Amyloid Change with 18F-Florbetapir PET and Standardized Uptake Value Ratios

(2015) S. M. Landau et al.   JOURNAL OF NUCLEAR MEDICINE

A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial

(2015) Tiia Ngandu et al.   LANCET

Trajectories of memory decline in preclinical Alzheimer's disease: results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing

(2015) Robert H. Pietrzak et al.   NEUROBIOLOGY OF AGING

Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease

(2015) Sebastian Palmqvist et al.   NEUROLOGY

Alzheimer's and Parkinson's diseases: The prion concept in relation to assembled A , tau, and  -synuclein

(2015) M. Goedert   SCIENCE

Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 β-Amyloid Measures Across the Spectrum of Alzheimer Disease

(2015) Jon B. Toledo et al.   JAMA Neurology

Predicting Reduction of Cerebrospinal Fluid β-Amyloid 42 in Cognitively Healthy Controls

(2015) Niklas Mattsson et al.   JAMA Neurology

mixtools: AnRPackage for Analyzing Finite Mixture Models

(2015) Tatiana Benaglia et al.   Journal of Statistical Software

Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease

(2014) Niklas Mattsson et al.   BRAIN

Pathways to Alzheimer's disease

(2014) J. Hardy et al.   JOURNAL OF INTERNAL MEDICINE

The Evolution of Preclinical Alzheimer’s Disease: Implications for Prevention Trials

(2014) Reisa Sperling et al.   NEURON

The A4 Study: Stopping AD Before Symptoms Begin?

(2014) R. A. Sperling et al.   Science Translational Medicine

Accuracy of Brain Amyloid Detection in Clinical Practice Using Cerebrospinal Fluid β-Amyloid 42

(2014) Sebastian Palmqvist et al.   JAMA Neurology

Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease

(2014) Niklas Mattsson et al.   Annals of Clinical and Translational Neurology

Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid-β changes occur before increases of tau in cerebrospinal fluid

(2013) Heiko Braak et al.   ACTA NEUROPATHOLOGICA

Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI

(2013) Jon B. Toledo et al.   ACTA NEUROPATHOLOGICA

Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid

(2013) Susan M. Landau et al.   ANNALS OF NEUROLOGY

In vivo characterization of the early states of the amyloid-beta network

(2013) Jorge Sepulcre et al.   BRAIN

Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study

(2013) Stephanie JB Vos et al.   LANCET NEUROLOGY

Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers

(2013) Clifford R Jack et al.   LANCET NEUROLOGY

Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study

(2013) Victor L Villemagne et al.   LANCET NEUROLOGY

Amyloid deposition, hypometabolism, and longitudinal cognitive decline

(2012) Susan M. Landau et al.   ANNALS OF NEUROLOGY

Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer’s disease: a voxelwise PiB–PET longitudinal study

(2012) Nicolas Villain et al.   BRAIN

Development and assessment of a composite score for memory in the Alzheimer’s Disease Neuroimaging Initiative (ADNI)

(2012) Paul K. Crane et al.   Brain Imaging and Behavior

Performance Characteristics of Amyloid PET with Florbetapir F 18 in Patients with Alzheimer's Disease and Cognitively Normal Subjects

(2012) A. D. Joshi et al.   JOURNAL OF NUCLEAR MEDICINE

Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers

(2012) M. Scholl et al.   NEUROLOGY

Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease

(2012) Randall J. Bateman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Development of Positron Emission Tomography β-Amyloid Plaque Imaging Agents

(2012) Chester A. Mathis et al.   SEMINARS IN NUCLEAR MEDICINE

Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh compound B units of brain Aβ amyloid

(2011) Stephen D. Weigand et al.   Alzheimers & Dementia

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Reisa A. Sperling et al.   Alzheimers & Dementia

The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Marilyn S. Albert et al.   Alzheimers & Dementia

Testing the Right Target and Right Drug at the Right Stage

(2011) R. A. Sperling et al.   Science Translational Medicine

Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly People

(2010) Geert De Meyer   ARCHIVES OF NEUROLOGY

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

(2009) Leslie M. Shaw et al.   ANNALS OF NEUROLOGY

APOEpredicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging

(2009) John C. Morris et al.   ANNALS OF NEUROLOGY

Absence of Pittsburgh Compound B Detection of Cerebral Amyloid β in a Patient With Clinical, Cognitive, and Cerebrospinal Fluid Markers of Alzheimer Disease

(2009) Nigel J. Cairns et al.   ARCHIVES OF NEUROLOGY

Beta Amyloid in Alzheimer's Disease: Increased Deposition in Brain Is Reflected in Reduced Concentration in Cerebrospinal Fluid

(2009) Timo Grimmer et al.   BIOLOGICAL PSYCHIATRY

Cerebrospinal fluid tau and ptau181increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease

(2009) Anne M. Fagan et al.   EMBO Molecular Medicine

Relationship of Cerebrospinal Fluid Markers to 11C-PiB and 18F-FDDNP Binding

(2009) N. Tolboom et al.   JOURNAL OF NUCLEAR MEDICINE

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

(2009) Clifford R Jack et al.   LANCET NEUROLOGY

Relationships between biomarkers in aging and dementia

(2009) W. J. Jagust et al.   NEUROLOGY

The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods

(2008) Clifford R. Jack et al.   JOURNAL OF MAGNETIC RESONANCE IMAGING